NASDAQ:LMNX - Luminex Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $33.32 -0.67 (-1.97 %) (As of 07/20/2018 04:00 PM ET)Previous Close$33.32Today's Range$33.26 - $33.9952-Week Range$18.62 - $34.49Volume284,792 shsAverage Volume295,059 shsMarket Capitalization$1.51 billionP/E Ratio36.62Dividend Yield0.71%Beta0.19 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group B strep assays, ARIES group A strep assays, ARIES bordetella assays, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas. Receive LMNX News and Ratings via Email Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical SymbolNASDAQ:LMNX CUSIP55027E10 Webwww.luminexcorp.com Phone512-219-8020 Debt Debt-to-Equity RatioN/A Current Ratio6.69 Quick Ratio5.20 Price-To-Earnings Trailing P/E Ratio36.62 Forward P/E Ratio44.43 P/E Growth3.3 Sales & Book Value Annual Sales$306.57 million Price / Sales4.83 Cash Flow$1.3826 per share Price / Cash24.10 Book Value$9.94 per share Price / Book3.35 Profitability EPS (Most Recent Fiscal Year)$0.91 Net Income$29.42 million Net Margins10.60% Return on Equity8.07% Return on Assets7.33% Miscellaneous Employees922 Outstanding Shares44,450,000Market Cap$1,510.79 Luminex (NASDAQ:LMNX) Frequently Asked Questions What is Luminex's stock symbol? Luminex trades on the NASDAQ under the ticker symbol "LMNX." How often does Luminex pay dividends? What is the dividend yield for Luminex? Luminex announced a quarterly dividend on Friday, May 18th. Investors of record on Friday, June 22nd will be paid a dividend of $0.06 per share on Friday, July 13th. This represents a $0.24 dividend on an annualized basis and a yield of 0.72%. The ex-dividend date of this dividend is Thursday, June 21st. View Luminex's Dividend History. How were Luminex's earnings last quarter? Luminex Co. (NASDAQ:LMNX) released its quarterly earnings results on Monday, May, 7th. The medical instruments supplier reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.08. The medical instruments supplier earned $82.60 million during the quarter, compared to analyst estimates of $80.52 million. Luminex had a net margin of 10.60% and a return on equity of 8.07%. The firm's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $0.28 EPS. View Luminex's Earnings History. When is Luminex's next earnings date? Luminex is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Luminex. What price target have analysts set for LMNX? 4 analysts have issued 1-year target prices for Luminex's shares. Their predictions range from $21.00 to $26.00. On average, they anticipate Luminex's share price to reach $23.00 in the next twelve months. This suggests that the stock has a possible downside of 31.0%. View Analyst Ratings for Luminex. What is the consensus analysts' recommendation for Luminex? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of Luminex's key competitors? Some companies that are related to Luminex include Insulet (PODD), Haemonetics (HAE), Globus Medical (GMED), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII) and Atrion (ATRI). Who are Luminex's key executives? Luminex's management team includes the folowing people: Mr. Nachum Shamir, CEO, Pres & Director (Age 64)Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 56)Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 50)Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 48)Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 56) Has Luminex been receiving favorable news coverage? News coverage about LMNX stock has been trending somewhat positive on Saturday, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Luminex earned a news sentiment score of 0.10 on Accern's scale. They also assigned headlines about the medical instruments supplier an impact score of 45.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. Who are Luminex's major shareholders? Luminex's stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.20%), Hartford Investment Management Co. (0.03%), Municipal Employees Retirement System of Michigan (0.03%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex. Which major investors are selling Luminex stock? LMNX stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Municipal Employees Retirement System of Michigan and Xact Kapitalforvaltning AB. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Insider Buying and Selling for Luminex. Which major investors are buying Luminex stock? LMNX stock was bought by a variety of institutional investors in the last quarter, including Hartford Investment Management Co.. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex. How do I buy shares of Luminex? Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Luminex's stock price today? One share of LMNX stock can currently be purchased for approximately $33.32. How big of a company is Luminex? Luminex has a market capitalization of $1.51 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe. How can I contact Luminex? Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected] MarketBeat Community Rating for Luminex (NASDAQ LMNX)Community Ranking: 1.8 out of 5 ()Outperform Votes: 158 (Vote Outperform)Underperform Votes: 274 (Vote Underperform)Total Votes: 432MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?